Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Bio-Techne ( (TECH) ).
On May 6, 2026, Bio-Techne reported third-quarter fiscal 2026 results showing a 2% decline in reported and organic revenue to $311.4 million, weighed by prior-year GMP fast‑track orders and timing of large commercial supply shipments. Despite the top-line softness, GAAP EPS more than doubled to $0.32 and GAAP operating margin rose to 24.2% on profitability initiatives, the Exosome Diagnostics divestiture, and the absence of a prior-year arbitration charge, even as adjusted EPS slipped to $0.53 and adjusted operating margin edged down to 34.2%.
Demand from large pharma remained a key growth engine with a sixth straight quarter of double-digit gains, helped by momentum in Asia and stabilizing low-single-digit growth in U.S. academic markets, while emerging biotech spending continued to lag. Segment performance was mixed: Protein Sciences saw a 1% sales decline and lower margins due to volume and product mix, whereas Diagnostics and Spatial Biology posted 3% organic growth and margin improvement, underscoring management’s focus on higher-growth applications like spatial biology and GMP proteins and reinforcing the company’s positioning for long-term value despite a still-mixed funding environment.
The most recent analyst rating on (TECH) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.
Overall score reflects pressured recent operating performance (declining TTM revenue and margin compression) partly offset by a strong balance sheet and positive cash generation. Technicals are supportive with the stock trending above key moving averages, but valuation is a major drag given the very high P/E and low yield. Earnings call guidance suggests timing-related headwinds should ease with continued margin improvement, supporting a mid-range score.
To see Spark’s full report on TECH stock, click here.
More about Bio-Techne
Bio-Techne Corporation is a Minnesota-headquartered global life sciences company supplying high-quality reagents, analytical instruments, and precision diagnostics to academic researchers, biopharmaceutical and biotechnology firms, and clinical diagnostic labs. Operating in 34 locations with around 3,100 employees and more than 500,000 products, it generated over $1.2 billion in fiscal 2025 net sales through its R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics brands, which span discovery research to clinical decision-making.
Average Trading Volume: 2,209,978
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.56B
Find detailed analytics on TECH stock on TipRanks’ Stock Analysis page.